Cas no 36940-87-1 (Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate))

Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate), is a modified cyclic adenosine monophosphate (cAMP) derivative with enhanced stability and bioavailability due to the hydrogen butanedioate (succinate) moiety. This compound serves as a key secondary messenger in cellular signaling pathways, regulating processes such as metabolism, gene expression, and ion transport. The succinate modification improves solubility and membrane permeability, making it advantageous for research applications requiring precise modulation of cAMP-dependent pathways. Its structural integrity under physiological conditions ensures reliable performance in biochemical assays and pharmacological studies. This derivative is particularly useful in investigating G-protein-coupled receptor (GPCR) mechanisms and intracellular signaling cascades.
Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) structure
36940-87-1 structure
Product Name:Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate)
CAS No:36940-87-1
MF:C14H16N5O9P
MW:429.278703689575
CID:309179
PubChem ID:24897315
Update Time:2025-11-01

Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) Chemical and Physical Properties

Names and Identifiers

    • Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate)
    • 2'- O- MONOSUCCINYLADENOSINE- 3', 5'- CYCLIC MONOPHOSPHATE ( 2'-O-MS-CAMP )
    • 2'-O-MONOSUCCINYLADENOSINE 3':5'-CYCLIC MONOPHOSPHATE
    • 2'-O-MONOSUCCINYLADENOSINE 3':5'-*CYCLIC MONOPHOSPH
    • Adenosine 3',5'-phosphoric acid 2'-hydrogen butanedioate
    • succinyladenosine 3',5'-cyclic monophosphate
    • 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin,adenosine deriv.
    • 2'-O-Succinyl-3',5'-cyclic AMP
    • 2'-O-Succinyl-cAMP
    • 2'-O-Succinyladenosine 3',5'-monophosphate
    • Adenosine cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen succinate)
    • Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate)
    • 2'-O-Monosuccinyladenosine 3',5'-cyclic monophosphate
    • EINECS 253-284-5
    • PD130987
    • 4-(((4AR,6R,7R,7aR)-6-(6-amino-9H-purin-9-yl)-2-hydroxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl)oxy)-4-oxobutanoic acid
    • CS-0140827
    • HY-131768
    • 4-{[(4aR,6R,7R,7aR)-6-(6-amino-9H-purin-9-yl)-2-hydroxy-2-oxo-hexahydro-2-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy}-4-oxobutanoic acid
    • 4-(((4AR,6R,7R,7aR)-6-(6-amino-9H-purin-9-yl)-2-hydroxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl)oxy)-4-oxobutanoicacid
    • 4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
    • AKOS030573821
    • 4-{[6-(6-Amino-9H-purin-9-yl)-2-hydroxy-2-oxotetrahydro-2H,4H-2lambda~5~-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy}-4-oxobutanoic acid
    • MFCD00037616
    • DTXSID50958128
    • 36940-87-1
    • DA-49453
    • 2'-O-succinyl cyclic AMP
    • QNPSLGPIZRJDAN-UISLRAPISA-N
    • Inchi： 1S/C14H16N5O9P/c15-12-9-13(17-4-16-12)19(5-18-9)14-11(27-8(22)2-1-7(20)21)10-6(26-14)3-25-29(23,24)28-10/h4-6,10-11,14H,1-3H2,(H,20,21)(H,23,24)(H2,15,16,17)/t6-,10-,11-,14-/m1/s1
    • InChI Key： QNPSLGPIZRJDAN-UISLRAPISA-N
    • SMILES： P1(=O)(O)OC[C@@H]2[C@H]([C@H]([C@H](N3C=NC4C(N)=NC=NC3=4)O2)OC(CCC(=O)O)=O)O1

Computed Properties

  • Exact Mass: 429.06900
  • Monoisotopic Mass: 429.06856410g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 3
  • Hydrogen Bond Acceptor Count: 13
  • Heavy Atom Count: 29
  • Rotatable Bond Count: 6
  • Complexity: 713
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -2.6
  • Topological Polar Surface Area: 198?2

Experimental Properties

  • PSA: 208.02000
  • LogP: 0.17950

Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) Security Information

  • Hazardous Material transportation number：NONH for all modes of transport
  • WGK Germany：3
  • Storage Condition：?20°C

Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHENG KE LU SI SHENG WU JI SHU
sc-214077-25mg
2'-O-Monosuccinyladenosine 3':5'-cyclic monophosphate,
 36940-87-1
25mg
 ￥1722.00 2023-09-05
SHENG KE LU SI SHENG WU JI SHU
sc-214077A-100mg
2'-O-Monosuccinyladenosine 3':5'-cyclic monophosphate,
 36940-87-1
100mg
 ￥5265.00 2023-09-05
SHENG KE LU SI SHENG WU JI SHU
sc-214077-25 mg
2'-O-Monosuccinyladenosine 3':5'-cyclic monophosphate,
 36940-87-1
25mg
 ￥1,722.00 2023-07-11
SHENG KE LU SI SHENG WU JI SHU
sc-214077A-100 mg
2'-O-Monosuccinyladenosine 3':5'-cyclic monophosphate,
 36940-87-1
100MG
 ￥5,265.00 2023-07-11
1PlusChem
1P00C10O-5mg
4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
 36940-87-1 ≥98%
5mg
 $119.00 2024-05-04
1PlusChem
1P00C10O-10mg
4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
 36940-87-1 ≥98%
10mg
 $192.00 2024-05-04
1PlusChem
1P00C10O-25mg
4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
 36940-87-1 ≥98%
25mg
 $342.00 2024-05-04
A2B Chem LLC
AF60392-5mg
4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
 36940-87-1 ≥98%
5mg
 $67.00 2024-04-20
A2B Chem LLC
AF60392-10mg
4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
 36940-87-1 ≥98%
10mg
 $126.00 2024-04-20
A2B Chem LLC
AF60392-25mg
4-[[(4aR,6R,7R,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl]oxy]-4-oxobutanoic acid
 36940-87-1 ≥98%
25mg
 $248.00 2024-04-20

Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) Suppliers

NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:36940-87-1)2′-O-Monosuccinyladenosine 3′:5′-cyclic monophosphate
Order Number:NC12359
Stock Status:
Quantity:10g
Purity:97%
Pricing Information Last Updated:Friday, 18 July 2025 16:06
Price ($):Price inquiry

Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) Related Literature

Related Categories

Additional information on Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate)

Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) and CAS No. 36940-87-1: A Comprehensive Overview

Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate), commonly referred to by its CAS number 36940-87-1, is a complex nucleotide derivative that has garnered significant attention in the field of biochemistry and pharmacology. This compound, often abbreviated as ADP-ribose, plays a crucial role in cellular signaling and energy metabolism. Its unique structure, featuring both phosphate and butanedioate groups, contributes to its multifaceted biological functions.

The primary significance of Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) lies in its involvement in various physiological processes. As a derivative of adenosine triphosphate (ATP), it is integral to the maintenance of cellular homeostasis. The compound's ability to interact with specific enzymes and receptors underscores its importance in modulating cellular responses. Recent studies have highlighted its role in regulating inflammation, neurotransmission, and cardiovascular function.

One of the most intriguing aspects of CAS No. 36940-87-1 is its application in therapeutic research. Researchers have been exploring its potential as a therapeutic agent due to its ability to modulate adenosine receptors (A1, A2A, A2B, and A3). These receptors are involved in a wide range of physiological processes, making ADP-ribose a promising candidate for treating conditions such as neurodegenerative diseases, cardiovascular disorders, and autoimmune diseases.

Recent advancements in the field have revealed novel mechanisms by which Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) exerts its effects. For instance, studies have demonstrated its ability to inhibit enzymes like poly(ADP-ribose) polymerases (PARPs), which are implicated in DNA repair and cell death processes. This has opened up new avenues for developing treatments for conditions associated with DNA damage and oxidative stress.

The compound's structural features also make it an attractive scaffold for drug design. The presence of both phosphate and butanedioate groups provides multiple sites for chemical modification, allowing researchers to tailor its properties for specific therapeutic applications. This flexibility has led to the development of several analogs with enhanced efficacy and reduced side effects.

In clinical trials, CAS No. 36940-87-1 has shown promise in treating various conditions. For example, studies have indicated that it may help reduce inflammation in chronic inflammatory diseases by modulating immune cell responses. Additionally, its ability to protect against neuronal damage has made it a candidate for treating neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The synthesis of Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) is another area of active research. Researchers have developed efficient synthetic routes that allow for the production of high-purity material suitable for both laboratory studies and clinical applications. These advancements have been crucial in facilitating further exploration of the compound's therapeutic potential.

The future prospects of Adenosine, cyclic 3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate) are vast. Ongoing research aims to uncover additional mechanisms by which it influences cellular processes and to develop novel derivatives with improved therapeutic profiles. As our understanding of its biology continues to grow, so too does the potential for translating these findings into effective treatments for a wide range of diseases.

36940-87-1 (Adenosine, cyclic3',5'-(hydrogen phosphate) 2'-(hydrogen butanedioate)) Related Products

Recommended suppliers
NewCan Biotech Limited
(CAS:36940-87-1)2′-O-Monosuccinyladenosine 3′:5′-cyclic monophosphate
NC12359
Purity:97%
Quantity:10g
Price ($):Inquiry
Email